Warrant Expiry and Block Admission Cancellation

Cambridge Nutritional Sciences PLC
10 November 2023
 



Cambridge Nutritional Sciences plc

(the 'Company' or 'CNS')

 

Warrant Expiry

 

and

 

Block Admission Cancellation

 

 

Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that all warrants issued alongside its capital raise announced 6 May 2022 have now expired ("Warrants").

 

Further to the above the Company has made application to AIM to cancel the Company's Block Admission, which was originally established to facilitate the issuance of ordinary shares following receipt of any exercise of the Warrants (the "Cancellation"). The Cancellation will become effective Monday 13 November, as such no further interim returns will be published in relation to the Company's Block Admission. The Balance of ordinary shares under the Block Admission not issued/allotted at the time of Cancellation is 90,000,000.

 

 

 

Contacts: 

 

Cambridge Nutritional Sciences plc

  www.cnsplc.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR





Cavendish Capital Markets Limited  

Tel: 020 7220 0500

Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)


Nigel Birks / Harriet Ward (ECM)






Walbrook PR Limited

Tel: 020 7933 8780 or CNS@walbrookpr.com

Paul McManus / Charlotte Edgar

Mob: 07980 541 893 / 07884 664 686

Sam Allen

Mob: 07502 558 258

 

 

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings